Literature DB >> 26791377

mTORC signaling in hematopoiesis.

Xiaomin Wang1, Yajing Chu1, Weili Wang1, Weiping Yuan2.   

Abstract

mTOR is a serine/threonine (Ser/Thr) protein kinase that responds to multiple signals, including growth factors, amino acids, energy status, stress, and oxygen, regulates cell survival, cell growth, the cell cycle, and cell metabolism, and maintains homeostasis [1]. Increased or decreased mTORC1 activity can alter HSC function and cause hematological disorders [2, 3]. Therefore, a comprehensive knowledge of mTOR is critical to understanding how HSCs function and maintain homeostasis in the hematopoietic system. In this review, we summarize recent advances in the understanding of the mTOR signaling pathway and its roles in hematopoiesis and leukemia. We also discuss pharmacological approaches to manipulate mTOR activity.

Entities:  

Keywords:  HSC; Hematopoiesis; Leukemia; Leukemogenesis; Targeted therapy; mTOR

Mesh:

Substances:

Year:  2016        PMID: 26791377     DOI: 10.1007/s12185-016-1944-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  97 in total

1.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

Authors:  L Willems; N Chapuis; A Puissant; T T Maciel; A S Green; N Jacque; C Vignon; S Park; S Guichard; O Herault; A Fricot; O Hermine; I C Moura; P Auberger; N Ifrah; F Dreyfus; D Bonnet; C Lacombe; P Mayeux; D Bouscary; J Tamburini
Journal:  Leukemia       Date:  2011-12-06       Impact factor: 11.528

2.  mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization.

Authors:  Boyi Gan; Ergün Sahin; Shan Jiang; Abel Sanchez-Aguilera; Kenneth L Scott; Lynda Chin; David A Williams; David J Kwiatkowski; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

3.  Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.

Authors:  Takeshi Kaizuka; Taichi Hara; Noriko Oshiro; Ushio Kikkawa; Kazuyoshi Yonezawa; Kenji Takehana; Shun-Ichiro Iemura; Tohru Natsume; Noboru Mizushima
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

4.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice.

Authors:  Jian Huang; Yi Zhang; Alexey Bersenev; W Timothy O'Brien; Wei Tong; Stephen G Emerson; Peter S Klein
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

Review 5.  PTEN mutation: many birds with one stone in tumorigenesis.

Authors:  Weijin Liu; Yonggang Zhou; Sven N Reske; Changxian Shen
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

6.  A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche.

Authors:  Yoon-Young Jang; Saul J Sharkis
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

7.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

8.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

9.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

10.  mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.

Authors:  Brandon R Beagle; Duc M Nguyen; Sharmila Mallya; Sarah S Tang; Mengrou Lu; Zhihong Zeng; Marina Konopleva; Thanh-Trang Vo; David A Fruman
Journal:  Oncotarget       Date:  2015-02-10
View more
  13 in total

Review 1.  Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Authors:  Yanan Gao; Chase Y Yuan; Weiping Yuan
Journal:  Stem Cell Investig       Date:  2016-07-22

Review 2.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

3.  Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP.

Authors:  Benjamin C Houghton; Neelam Panchal; Simone A Haas; Kay O Chmielewski; Markus Hildenbeutel; Thomas Whittaker; Claudio Mussolino; Toni Cathomen; Adrian J Thrasher; Claire Booth
Journal:  Front Genome Ed       Date:  2022-05-23

4.  The Molecular Signature of Megakaryocyte-Erythroid Progenitors Reveals a Role for the Cell Cycle in Fate Specification.

Authors:  Yi-Chien Lu; Chad Sanada; Juliana Xavier-Ferrucio; Lin Wang; Ping-Xia Zhang; H Leighton Grimes; Meenakshi Venkatasubramanian; Kashish Chetal; Bruce Aronow; Nathan Salomonis; Diane S Krause
Journal:  Cell Rep       Date:  2018-11-20       Impact factor: 9.423

Review 5.  Targeting mTOR in Acute Lymphoblastic Leukemia.

Authors:  Carolina Simioni; Alberto M Martelli; Giorgio Zauli; Elisabetta Melloni; Luca M Neri
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

6.  Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.

Authors:  Zhengwu Cheng; Xinyu Shao; Menglin Xu; Junfeng Wang; Xiaoyi Kuai; Liping Zhang; Jian Wu; Chunli Zhou; Jiading Mao
Journal:  Oncol Rep       Date:  2019-03-15       Impact factor: 3.906

7.  Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank.

Authors:  Shu-Hong Lin; Derek W Brown; Brandon Rose; Felix Day; Olivia W Lee; Sairah M Khan; Jada Hislop; Stephen J Chanock; John R B Perry; Mitchell J Machiela
Journal:  Cell Biosci       Date:  2021-07-23       Impact factor: 7.133

8.  Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.

Authors:  Yanan Gao; Juan Gao; Minghao Li; Yawei Zheng; Yajie Wang; Hongyan Zhang; Weili Wang; Yajing Chu; Xiaomin Wang; Mingjiang Xu; Tao Cheng; Zhenyu Ju; Weiping Yuan
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

Review 9.  DNA Damage Response in Hematopoietic Stem Cell Ageing.

Authors:  Tangliang Li; Zhong-Wei Zhou; Zhenyu Ju; Zhao-Qi Wang
Journal:  Genomics Proteomics Bioinformatics       Date:  2016-05-21       Impact factor: 7.691

10.  Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.

Authors:  Menglin Xu; Xinyu Shao; Xiaoyi Kuai; Liping Zhang; Chunli Zhou; Zhengwu Cheng
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.